Subscribe to news

Press Center

26.05.2014
OJSC HSCI, announced its unaudited unconsolidated results for the first quarter of 2014 in accordance with the Russian Accounting Standards (RAS)
21.05.2014
The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies, today announced the decision of the Company’s Board of Directors to recommend the following annual dividends for 2013 to the Annual General Shareholder’s Meeting
06.05.2014
The Human Stem Cells Institute, today announced its audited consolidated results for the full year ended December 31, 2013 in accordance with International Financial Reporting Standards (IFRS):
28.04.2014
The Human Stem Cells Institute, today announced the decision of the Company’s Board of Directors on convocation of the Annual General Shareholders’ Meeting upon the results of 2013.
03.04.2014
The Human Stem Cells Institute, one of Russia’s leading biotech companies, announces the results of its Extraordinary General Shareholders’ Meeting (EGSM).
03.04.2014
The Human Stem Cells Institute, one of Russia’s leading biotech companies, today announced its audited unconsolidated results for 2013 in accordance with the Russian Accounting Standards (RAS)
07.03.2014
The Human Stem Cells Institute, today announced the decision of its Board of Directors on the lists of candidates to the Board of Directors and the Audit Commission of the Company to be elected at the Annual General Shareholders’ Meeting.
19.02.2014
The Human Stem Cells Institute, announces the signing of an investment agreement with RVC Biofund.
18.02.2014
Human Stem Cells Institute (HSCI), one of Russia's leading biotech companies (MOEX: ISKJ ), announcedthe transfer of its share in the charter capital of SynBio LLC to the IceGen LLC in the form of an additional contribution to the charter capital of the latter.
14.02.2014
OJSC HSCI, today announces that the Ministry of Industry and Trade of the Russian Federation has issued the Human Stem Cells Institute (HSCI) a license “To engage in the production of medicinal products” (No.12785-LS-P dated 31 December 2013).